Health Trials

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

ConditionIgA Nephropathy (IgAN)
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorWuhan Createrna Science and Technology Co., Ltd

About this trial

Efficacy and safety of MY008211A in IgAN patients

Eligibility criteria

Qualifiers

Males or females ≥ 18 and ≤ 75 years of age at Screening.

Estimated GFR(eGFR) ≥30 mL/min/1.73m2.

Subjects with a biopsy-confirmed diagnosis of IgAN.

Urine protein ≥0.75 g/24h from a 24h urine collection.

Disqualifiers

Systolic blood pressure >130 mm Hg or diastolic blood pressure >80 mm Hg.

Presence of any secondary IgAN.

Presence of rapidly progressive glomerulonephritis.

Presence of other chronic kidney diseases.

Trial design

Treatments tested in this trial

  • MY008211A tablets
  • MY008211A tablets matched placebo

Treatment groups

72 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Wuhan Createrna Science and Technology Co., Ltd

Lead sponsor

Source ClinicalTrials.gov